NTRK1 and lung carcinoma: It can drive resistance of tumours to receptor tyrosine kinase inhibition, demonstrating the potential of targeting NF-κB to improve patient outcome in EGFR mutant lung cancer sufferers treated with receptor tyrosine kinase inhibitors [152].